Effect of aging and long-term erectile function after XXXX -125 prostate brachytherapy.

@entity1 @entity1496 @entity323 @entity101 @entity6 @entity342
PURPOSE: To evaluate long-term erectile function (EF) in @entity1 treated with @entity1496 -125 prostate brachytherapy (PB) and to determine factors predictive for @entity323 ( @entity323 ), including natural decline because of aging. METHODS: Two thousand nine hundred twenty-nine @entity1 (implanted July 1989-June 2012) with baseline EF and greater than 10-month followup (FU) are included. About 78.9% had full and 7.9% had partial EF at baseline. EF was assessed on a physician-reported three-point scale. Poisson regression with generalized estimating equations was used to assess predictors of @entity323 and Kaplan-Meier curves time to @entity323 . The effect of aging was calculated from the declining rate of baseline EF seen in sequential 5-year age cohorts and from the Massachusetts Male Aging Study. RESULTS: The median age was 66  years and median FU 3.5  years (maximum 14 years). About 1142 @entity1 had more than 5  years of FU, and 43% had received 6 months of @entity342 deprivation therapy (ADT). Significant drop in EF was seen at 6  weeks after PB, with gradual decline thereafter. EF preservation at 5  years for age younger than 55, 56-59, 60-64, 65-69, and 70  year and older was 82%, 73%, 58%, 39%, and 23%, respectively. Comparisons of the 5-year age-related and treatment-related EF decline show that 50% of the long-term EF decline is related to aging. On univariate and multivariate analyses, age at implant, length of FU, @entity101 , @entity6 , and use of ADT (all p  <  0.01) were significant predictors of @entity323 . CONCLUSION: More than 80% of young @entity1 have EF preserved 5  years after PB. Age, ADT, history of @entity101 , and the natural decline in EF have negative impact on long-term EF after PB.
